Teclistamab

Teclistamab is a bispecific antibody utilized in the treatment of relapsed or refractory multiple myeloma. Its mechanism of action involves the simultaneous binding to two different antigens, facilitating immune system engagement. Specifically, Teclistamab targets the B-cell maturation antigen (BCMA) on multiple myeloma cells and CD3 on T cells. By bridging these two cell types, it effectively redirects T cells to the myeloma cells, leading to T cell activation and subsequent cancer cell lysis.

The BCMA target is crucial because it is predominantly expressed on the surface of multiple myeloma cells, making it an effective therapeutic target. By engaging with CD3 on T cells, Teclistamab stimulates T cell proliferation and cytokine release, which enhances the immune response against malignant cells. This mechanism contributes to the reduction of tumor burden in patients with multiple myeloma.

Evidence indicates that Teclistamab, as a BCMA-targeted therapy, is part of a new era of treatment strategies for multiple myeloma. It offers an innovative approach by leveraging the specificity of bispecific antibodies to recruit and activate the body's own immune system against cancer cells.

(Note: This content is informational and not a substitute for professional medical advice. Always consult a healthcare provider for medical guidance.)